The cost-effectiveness of natalizumab in patients with relapsing multiple sclerosis

被引：0
|
作者：
Meyer, K. [1 ]
Chiao, E. [1 ]
机构：
[1] Xcenda, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)68808-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A89 / A89
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN RUSSIA
    Matveev, N., V
    Sabanov, A., V
    Luneva, A., V
    VALUE IN HEALTH, 2014, 17 (03) : A60 - A60
  • [2] Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
    Mehdi Rezaee
    Mohammad Hossein Morowvat
    Maryam Poursadeghfard
    Armin Radgoudarzi
    Khosro Keshavarz
    BMC Health Services Research, 22
  • [3] Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
    Rezaee, Mehdi
    Morowvat, Mohammad Hossein
    Poursadeghfard, Maryam
    Radgoudarzi, Armin
    Keshavarz, Khosro
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [4] Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis
    Chiao, Evelyn
    Meyer, Kellie
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (06) : 1445 - 1454
  • [5] Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran
    Rezaee, Mehdi
    Izadi, Sadegh
    Keshavarz, Khosro
    Borhanihaghighi, Afshin
    Ravangard, Ramin
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 297 - 305
  • [6] Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia
    Lasalvia, Pieralessandro
    Hernandez, Fabian
    Castaneda-Cardona, Camilo
    Andres Cuestas, J.
    Rosselli, Diego
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 13 - 18
  • [7] Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
    Ayati, Nayyereh
    Taheri, Saeed
    Sahraian, Mohammad Ali
    Nikfar, Shekoufeh
    CURRENT JOURNAL OF NEUROLOGY, 2021, 20 (03): : 154 - 161
  • [8] COST-EFFECTIVENESS OF ESCALATING TO NATALIZUMAB OR SWITCHING AMONG IMMUNOMODULATORS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Furneri, G.
    Santoni, L.
    Ricella, C.
    Prosperini, L.
    VALUE IN HEALTH, 2015, 18 (07) : A695 - A695
  • [9] Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden
    O'Day, Ken
    Meyer, Kellie
    Stafkey-Mailey, Dana
    Watson, Crystal
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 295 - 302
  • [10] Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review
    Koeser, Leonardo
    McCrone, Paul
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (02) : 171 - 182
12345